{"transactions":[{"id":3391249,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":11958,"kind":"organization","name":"Temasek Holdings (Private) Ltd","position":1,"cik":"0001021944","reported_name":"Temasek Holdings (Private) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89168,"kind":"organization","name":"Fullerton Management Pte Ltd","position":2,"cik":"0001379348","reported_name":"Fullerton Management Pte Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89167,"kind":"organization","name":"Temasek Life Sciences Private Ltd","position":3,"cik":"0001379349","reported_name":"Temasek Life Sciences Private Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89166,"kind":"organization","name":"TLS Beta Pte. Ltd.","position":4,"cik":"0001673754","reported_name":"TLS Beta Pte. Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":99930,"kind":"organization","name":"V-Sciences Investments Pte Ltd","position":5,"cik":"0001379350","reported_name":"V-Sciences Investments Pte Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2019-10-18T20:16:05.000Z","date":"2019-10-16","kind":"exercise","acquired":false,"shares":1666666,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer.  Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer.  Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer.  Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer.  Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer.  Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer.  Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1666666},"source":{"system":"sec-edgar","filing":"0000899243-19-025766","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1021944/000089924319025766/doc4.xml","form_type":"4"}},{"id":3391248,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":11958,"kind":"organization","name":"Temasek Holdings (Private) Ltd","position":1,"cik":"0001021944","reported_name":"Temasek Holdings (Private) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89168,"kind":"organization","name":"Fullerton Management Pte Ltd","position":2,"cik":"0001379348","reported_name":"Fullerton Management Pte Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89167,"kind":"organization","name":"Temasek Life Sciences Private Ltd","position":3,"cik":"0001379349","reported_name":"Temasek Life Sciences Private Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89166,"kind":"organization","name":"TLS Beta Pte. Ltd.","position":4,"cik":"0001673754","reported_name":"TLS Beta Pte. Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":99930,"kind":"organization","name":"V-Sciences Investments Pte Ltd","position":5,"cik":"0001379350","reported_name":"V-Sciences Investments Pte Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2019-10-18T20:16:05.000Z","date":"2019-10-16","kind":"exercise","acquired":false,"shares":3333333,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A-1 Preferred Stock of Vir Biotechnology, Inc. (the \"Issuer\") held of record by TLS Beta Pte. Ltd. (\"TLS Beta\") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A-1 Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A-1 Preferred Stock, subject to adjustment and had no expiration date."},{"field":"shares","element":"transactionShares","label":"F1","text":"The Series A-1 Preferred Stock of Vir Biotechnology, Inc. (the \"Issuer\") held of record by TLS Beta Pte. Ltd. (\"TLS Beta\") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A-1 Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A-1 Preferred Stock, subject to adjustment and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A-1 Preferred Stock of Vir Biotechnology, Inc. (the \"Issuer\") held of record by TLS Beta Pte. Ltd. (\"TLS Beta\") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A-1 Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A-1 Preferred Stock, subject to adjustment and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A-1 Preferred Stock of Vir Biotechnology, Inc. (the \"Issuer\") held of record by TLS Beta Pte. Ltd. (\"TLS Beta\") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A-1 Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A-1 Preferred Stock, subject to adjustment and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A-1 Preferred Stock of Vir Biotechnology, Inc. (the \"Issuer\") held of record by TLS Beta Pte. Ltd. (\"TLS Beta\") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A-1 Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A-1 Preferred Stock, subject to adjustment and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Series A-1 Preferred Stock of Vir Biotechnology, Inc. (the \"Issuer\") held of record by TLS Beta Pte. Ltd. (\"TLS Beta\") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A-1 Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A-1 Preferred Stock, subject to adjustment and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3333333},"source":{"system":"sec-edgar","filing":"0000899243-19-025766","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1021944/000089924319025766/doc4.xml","form_type":"4"}},{"id":3391247,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":11958,"kind":"organization","name":"Temasek Holdings (Private) Ltd","position":1,"cik":"0001021944","reported_name":"Temasek Holdings (Private) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89168,"kind":"organization","name":"Fullerton Management Pte Ltd","position":2,"cik":"0001379348","reported_name":"Fullerton Management Pte Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89167,"kind":"organization","name":"Temasek Life Sciences Private Ltd","position":3,"cik":"0001379349","reported_name":"Temasek Life Sciences Private Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89166,"kind":"organization","name":"TLS Beta Pte. Ltd.","position":4,"cik":"0001673754","reported_name":"TLS Beta Pte. Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":99930,"kind":"organization","name":"V-Sciences Investments Pte Ltd","position":5,"cik":"0001379350","reported_name":"V-Sciences Investments Pte Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-10-18T20:16:05.000Z","date":"2019-10-16","kind":"purchase","acquired":true,"shares":500000,"price":20,"value":10000000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Consists of 500,000 shares of Common Stock held of record by V-Sciences Investments Pte Ltd (\"V-Sciences\") which were purchased in the Issuer's initial public offering at a price of $20.00 per share. V-Sciences Investments Pte Ltd is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited (\"TLS\") is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd (\"FMPL\"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited (\"Temasek\"). TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by V-Sciences. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":5499999,"source":{"system":"sec-edgar","filing":"0000899243-19-025766","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1021944/000089924319025766/doc4.xml","form_type":"4"}},{"id":3391246,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":11958,"kind":"organization","name":"Temasek Holdings (Private) Ltd","position":1,"cik":"0001021944","reported_name":"Temasek Holdings (Private) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89168,"kind":"organization","name":"Fullerton Management Pte Ltd","position":2,"cik":"0001379348","reported_name":"Fullerton Management Pte Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89167,"kind":"organization","name":"Temasek Life Sciences Private Ltd","position":3,"cik":"0001379349","reported_name":"Temasek Life Sciences Private Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89166,"kind":"organization","name":"TLS Beta Pte. Ltd.","position":4,"cik":"0001673754","reported_name":"TLS Beta Pte. Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":99930,"kind":"organization","name":"V-Sciences Investments Pte Ltd","position":5,"cik":"0001379350","reported_name":"V-Sciences Investments Pte Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-10-18T20:16:05.000Z","date":"2019-10-16","kind":"exercise","acquired":true,"shares":1666666,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer.  Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Consists of 1,666,666 shares of Common Stock held of record by TLS Beta."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":4999999,"source":{"system":"sec-edgar","filing":"0000899243-19-025766","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1021944/000089924319025766/doc4.xml","form_type":"4"}},{"id":3391245,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":11958,"kind":"organization","name":"Temasek Holdings (Private) Ltd","position":1,"cik":"0001021944","reported_name":"Temasek Holdings (Private) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89168,"kind":"organization","name":"Fullerton Management Pte Ltd","position":2,"cik":"0001379348","reported_name":"Fullerton Management Pte Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89167,"kind":"organization","name":"Temasek Life Sciences Private Ltd","position":3,"cik":"0001379349","reported_name":"Temasek Life Sciences Private Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89166,"kind":"organization","name":"TLS Beta Pte. Ltd.","position":4,"cik":"0001673754","reported_name":"TLS Beta Pte. Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":99930,"kind":"organization","name":"V-Sciences Investments Pte Ltd","position":5,"cik":"0001379350","reported_name":"V-Sciences Investments Pte Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-10-18T20:16:05.000Z","date":"2019-10-16","kind":"exercise","acquired":true,"shares":3333333,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A-1 Preferred Stock of Vir Biotechnology, Inc. (the \"Issuer\") held of record by TLS Beta Pte. Ltd. (\"TLS Beta\") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A-1 Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A-1 Preferred Stock, subject to adjustment and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Consists of 3,333,333 shares of Common Stock held of record by TLS Beta."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":3333333,"source":{"system":"sec-edgar","filing":"0000899243-19-025766","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1021944/000089924319025766/doc4.xml","form_type":"4"}},{"id":3970515,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":11958,"kind":"organization","name":"Temasek Holdings (Private) Ltd","position":1,"cik":"0001021944","reported_name":"Temasek Holdings (Private) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89168,"kind":"organization","name":"Fullerton Management Pte Ltd","position":2,"cik":"0001379348","reported_name":"Fullerton Management Pte Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89167,"kind":"organization","name":"Temasek Life Sciences Private Ltd","position":3,"cik":"0001379349","reported_name":"Temasek Life Sciences Private Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89166,"kind":"organization","name":"TLS Beta Pte. Ltd.","position":4,"cik":"0001673754","reported_name":"TLS Beta Pte. Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":99930,"kind":"organization","name":"V-Sciences Investments Pte Ltd","position":5,"cik":"0001379350","reported_name":"V-Sciences Investments Pte Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2018-04-04T17:33:53.000Z","date":"2018-04-02","kind":"exercise","acquired":false,"shares":989612,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer.  Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer.  Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer.  Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer.  Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer.  Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer.  Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":989612},"source":{"system":"sec-edgar","filing":"0000899243-18-009413","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1021944/000089924318009413/doc4.xml","form_type":"4"}},{"id":3970514,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":11958,"kind":"organization","name":"Temasek Holdings (Private) Ltd","position":1,"cik":"0001021944","reported_name":"Temasek Holdings (Private) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89168,"kind":"organization","name":"Fullerton Management Pte Ltd","position":2,"cik":"0001379348","reported_name":"Fullerton Management Pte Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89167,"kind":"organization","name":"Temasek Life Sciences Private Ltd","position":3,"cik":"0001379349","reported_name":"Temasek Life Sciences Private Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89166,"kind":"organization","name":"TLS Beta Pte. Ltd.","position":4,"cik":"0001673754","reported_name":"TLS Beta Pte. Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":99930,"kind":"organization","name":"V-Sciences Investments Pte Ltd","position":5,"cik":"0001379350","reported_name":"V-Sciences Investments Pte Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2018-04-04T17:33:53.000Z","date":"2018-04-02","kind":"exercise","acquired":false,"shares":1605681,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Stock of Homology Medicines, Inc. (the \"Issuer\") held of record by TLS Beta Pte. Ltd. (\"TLS Beta\") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A Preferred Stock, subject to adjustment and had no expiration date."},{"field":"shares","element":"transactionShares","label":"F1","text":"The Series A Preferred Stock of Homology Medicines, Inc. (the \"Issuer\") held of record by TLS Beta Pte. Ltd. (\"TLS Beta\") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A Preferred Stock, subject to adjustment and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Stock of Homology Medicines, Inc. (the \"Issuer\") held of record by TLS Beta Pte. Ltd. (\"TLS Beta\") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A Preferred Stock, subject to adjustment and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Stock of Homology Medicines, Inc. (the \"Issuer\") held of record by TLS Beta Pte. Ltd. (\"TLS Beta\") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A Preferred Stock, subject to adjustment and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Preferred Stock of Homology Medicines, Inc. (the \"Issuer\") held of record by TLS Beta Pte. Ltd. (\"TLS Beta\") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A Preferred Stock, subject to adjustment and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Series A Preferred Stock of Homology Medicines, Inc. (the \"Issuer\") held of record by TLS Beta Pte. Ltd. (\"TLS Beta\") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A Preferred Stock, subject to adjustment and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1605681},"source":{"system":"sec-edgar","filing":"0000899243-18-009413","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1021944/000089924318009413/doc4.xml","form_type":"4"}},{"id":3970513,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":11958,"kind":"organization","name":"Temasek Holdings (Private) Ltd","position":1,"cik":"0001021944","reported_name":"Temasek Holdings (Private) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89168,"kind":"organization","name":"Fullerton Management Pte Ltd","position":2,"cik":"0001379348","reported_name":"Fullerton Management Pte Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89167,"kind":"organization","name":"Temasek Life Sciences Private Ltd","position":3,"cik":"0001379349","reported_name":"Temasek Life Sciences Private Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89166,"kind":"organization","name":"TLS Beta Pte. Ltd.","position":4,"cik":"0001673754","reported_name":"TLS Beta Pte. Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":99930,"kind":"organization","name":"V-Sciences Investments Pte Ltd","position":5,"cik":"0001379350","reported_name":"V-Sciences Investments Pte Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-04-04T17:33:53.000Z","date":"2018-04-02","kind":"purchase","acquired":true,"shares":625000,"price":16,"value":10000000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Consists of 625,000 shares of Common Stock held of record by V-Sciences Investments Pte Ltd (\"V-Sciences\") which were purchased in the Issuer's initial public offering at a price of $16.00 per share. V-Sciences Investments Pte Ltd is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited (\"TLS\") is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd (\"FMPL\"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited (\"Temasek\"). TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by V-Sciences."}],"balance_after":3220293,"source":{"system":"sec-edgar","filing":"0000899243-18-009413","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1021944/000089924318009413/doc4.xml","form_type":"4"}},{"id":3970512,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":11958,"kind":"organization","name":"Temasek Holdings (Private) Ltd","position":1,"cik":"0001021944","reported_name":"Temasek Holdings (Private) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89168,"kind":"organization","name":"Fullerton Management Pte Ltd","position":2,"cik":"0001379348","reported_name":"Fullerton Management Pte Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89167,"kind":"organization","name":"Temasek Life Sciences Private Ltd","position":3,"cik":"0001379349","reported_name":"Temasek Life Sciences Private Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89166,"kind":"organization","name":"TLS Beta Pte. Ltd.","position":4,"cik":"0001673754","reported_name":"TLS Beta Pte. Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":99930,"kind":"organization","name":"V-Sciences Investments Pte Ltd","position":5,"cik":"0001379350","reported_name":"V-Sciences Investments Pte Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-04-04T17:33:53.000Z","date":"2018-04-02","kind":"exercise","acquired":true,"shares":989612,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer.  Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Consists of 989,612 shares of Common Stock held of record by TLS Beta."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta."}],"balance_after":2595293,"source":{"system":"sec-edgar","filing":"0000899243-18-009413","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1021944/000089924318009413/doc4.xml","form_type":"4"}},{"id":3970511,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":11958,"kind":"organization","name":"Temasek Holdings (Private) Ltd","position":1,"cik":"0001021944","reported_name":"Temasek Holdings (Private) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89168,"kind":"organization","name":"Fullerton Management Pte Ltd","position":2,"cik":"0001379348","reported_name":"Fullerton Management Pte Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89167,"kind":"organization","name":"Temasek Life Sciences Private Ltd","position":3,"cik":"0001379349","reported_name":"Temasek Life Sciences Private Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89166,"kind":"organization","name":"TLS Beta Pte. Ltd.","position":4,"cik":"0001673754","reported_name":"TLS Beta Pte. Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":99930,"kind":"organization","name":"V-Sciences Investments Pte Ltd","position":5,"cik":"0001379350","reported_name":"V-Sciences Investments Pte Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-04-04T17:33:53.000Z","date":"2018-04-02","kind":"exercise","acquired":true,"shares":1605681,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Stock of Homology Medicines, Inc. (the \"Issuer\") held of record by TLS Beta Pte. Ltd. (\"TLS Beta\") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A Preferred Stock, subject to adjustment and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Consists of 1,605,681 shares of Common Stock held of record by TLS Beta."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta."}],"balance_after":1605681,"source":{"system":"sec-edgar","filing":"0000899243-18-009413","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1021944/000089924318009413/doc4.xml","form_type":"4"}}]}